Skip to main content

Table 1 Baseline demographic and clinical characteristics of SCD patients prescribed HU

From: Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study

Patient characteristics Sickle cell patients prescribed HU
(N = 3999)
N/Mean %/SD
Age (years) 19.24 11.85
Age Group
 < 2 26 0.7%
 2–5 327 8.2%
 6–11 786 19.7%
 12–17 933 23.3%
 18–30 1272 31.8%
 31–45 501 12.5%
 ≥ 46 154 3.9%
Sex
 Male 2033 50.8%
 Female 1966 49.2%
Race/Ethnicity
 White 111 2.8%
 Black 2933 73.3%
 Hispanic 296 7.4%
 Other 33 0.8%
 Unknown 626 15.7%
Geographic Region
 Northeast 1335 33.4%
 North Central 590 14.8%
 South 1501 37.5%
 West 573 14.3%
Charlson Comorbidity Index Score 0.60 0.99
 0 2447 61.2%
 1 1035 25.9%
 2–3 440 11.0%
 4+ 77 1.9%
Individual Comorbid Conditions (≥5%)
 Fever 1255 31.4%
 Asthma 811 20.3%
 Infectious and parasitic diseases 798 20.0%
 Acute chest syndrome 623 15.6%
 Constipation 485 12.1%
Upper respiratory tract infections 462 11.6%
Aseptic (avascular) bone necrosis 307 7.7%
Iron overload 298 7.5%
Gallstones 214 5.4%
Chronic pain 205 5.1%
Neoplasms benign and malignant 198 5.0%
Sepsis 198 5.0%
  1. HU hydroxyurea, SCD sickle cell disease, SD standard deviation